Key facts, as of
As of October 13, 2026, Stryker Corporation (SYK) trades at $282.60, down 22.5% over the past year. Its 52-week range runs from $267.00 to $392.55; the price is 28.0% below that high. It is 30.4% below its all-time high of $406.19, reached in January 2025. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +164.2%, against +312.9% for the S&P 500 (SPY). It sits 13.8% below its 200-day average of $327.96, the usual sign of a long-term downtrend. Its 30-day volatility is 22.4% annualized, which we rate medium risk. It has a trailing P/E of 29.8 and a dividend yield of 1.25%.
Cite: Portfolio Terminal, "Stryker Corporation (SYK) stock analysis", 2026-10-13. https://portfolio-terminal.com/analyse/syk
Where it trades today
trading 12% of the way up its 52-week range
How the price has moved
How far it is from its record
Stryker Corporation (SYK) is 30.4% below its all-time high of $406.19, reached in January 2025. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +164.2%, against +312.9% for the S&P 500 (SPY).
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- SYK trades at 29.8x earnings, well above the healthcare average of 22.0x, so the market is already pricing in above-consensus execution.
- SYK carries a beta of 0.78, which means the stock should be judged on how it affects total portfolio swings, not just on standalone upside.
- Relative performance versus UNH, JNJ, PFE matters here because leadership inside healthcare rarely stays static for long.
Portfolio Use Case
- SYK is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in SYK.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
- The view would need revisiting if peers such as UNH, JNJ, PFE start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for SYK come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for SYK. Last refresh: Oct 13, 2026, 9:18 AM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Stryker Corporation does
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical…
What analysts expect
SYK carries a buy consensus from 26 analysts, with an average price target of $362.62 versus $282.60 today (+28.3%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
SYK generated $25.84B in trailing revenue (9.4% year over year), with a 14.4% net margin, and $4.11B of free cash flow, against $11.97B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $25.12B | $16.07B | $5.06B | $3.25B | $8.49 | $4.28B |
| 2024 | $22.59B | $14.44B | $4.67B | $2.99B | $7.86 | $3.49B |
| 2023 | $20.50B | $13.06B | $3.92B | $3.17B | $8.34 | $3.14B |
| 2022 | $18.45B | $11.58B | $3.11B | $2.36B | $6.23 | $2.04B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
SYK is in 9 of the 30 ETFs we track. It weighs most in XLV: 1.52% of the fund, holding #18 of 62.
Famous investors who hold it
SYK is in the latest 13F of 1 of the 15 famous investors we follow. Terry Smith (Fundsmith) holds the most of it: 6.72% of the portfolio, position #2 of 41, as of Q2 2026.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
SYK beside the healthcare names it is usually measured against.
What the chart is saying
In a downtrend, with $267.85 the next floor.
downtrend- Price is 7.0% below its 50-day average and 13.8% below its 200-day.
- RSI at 48 is neither stretched nor washed out.
- The nearest ceiling is $290.74 (+2.9%), the nearest floor $267.85 (-5.2%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is SYK a good investment in 2026?
Stryker Corporation trades at a P/E ratio of 29.8, with medium volatility (22.4% annualized). The stock is in a consolidation phase.
What is the risk level of SYK?
Based on 30-day volatility of 22.4%, SYK has MEDIUM risk. Beta of 0.78 indicates lower sensitivity to market movements than average.
Does SYK pay dividends?
Yes, Stryker Corporation has a dividend yield of 1.25%.
How far is SYK from its all-time high?
Stryker Corporation is 30.4% below its all-time high of $406.19, reached in January 2025. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +164.2%, against +312.9% for the S&P 500 (SPY).
Which ETFs hold SYK?
9 of the 30 popular ETFs we track hold Stryker Corporation. The largest weights: XLV (1.52%), JEPI (0.65%), VIG (0.48%), VTV (0.20%) and VOO (0.17%). Measured on each issuer's full holdings file, dated August 31 to September 24, 2026.
How much of VOO is SYK?
0.17%, as of August 31, 2026: SYK is holding #106 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $1.69 in Stryker Corporation.
Which famous investors own SYK?
Terry Smith (6.72% of Fundsmith's 13F), according to their latest Form 13F filings with the SEC (Q2 2026). A 13F lists US long positions 45 days after the quarter ends, so it can be out of date.
What is the analyst price target for SYK?
The average analyst price target for Stryker Corporation (SYK) is $362.62 based on 26 analyst estimates, about 28.3% above the current price of $282.60. The published range runs from $298.00 to $465.00.
How much revenue does SYK generate?
Stryker Corporation reported $25.84B in trailing twelve-month revenue. Revenue growth is running at 9.4% year over year. Net margin sits at 14.4%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare SYK with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.